THERAPY DOSSIER · th-ab28ec866909

Silybum marianum and Taraxacum officinale extracts

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03687073 ↗PHASE1completed

Trial of Indole-3-Carbinol & Silibinin (Silybum marianum) in Smokers

Smoking

Enrolment: 21 · Results not recorded

NCT01436929 ↗NAunknown

Prophylactic Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs

Tuberculosis

Enrolment: 600 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27845613 ↗2016Reported benefit

Protective effect of Silybum marianum and Taraxacum officinale extracts against oxidative kidney injuries induced by carbon tetrachloride in rats.

RatChemical/toxinWistar albinoFemalen = 66 female rats in total across six groups, n per group not…Oral gavage100 mg/kg/day of each extractPretreatment, extracts started 10 days before CCl4 administration

Model: Carbon tetrachloride induced oxidative kidney injury, CCl4 in olive oil 1:1 at 1.5 mL/kg intraperitoneally

Both extracts reduced CCl4-induced rises in serum ALP, GGT and renal MDA and restored GSH and glutathione-dependent enzyme activities with improved histopathology, with Silybum marianum the more effective of the two.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…